Skip to content
thestock.space

RPG Life Sciences (RPGLIFE) had a P/E of 38.1× on 6 Nov 2026, above the industry P/E of 28.7×, and the shares are 18% below their 52-week high. Sales and net profit grew 11% and 19% a year over 3 years; its ROCE of 25% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It carries very little debt, and its dividend yield is 0.9%. It is a small-cap company with a market cap of ₹4,224 Cr, ranked 47th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 5.4% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹2,580.00
Day high
₹2,580.00
Day low
₹2,520.10
Prev. close
₹2,595.70
Volume
7K

Health check

2 good · 4 to check
  • ReturnsBehind

    +5.4% over a year, better than 1 of 7 peers.

  • Price tagPricier

    P/E 38.1 vs industry 28.7.

  • GrowthStrong

    Sales +11.3%, profit +19.4% a year over 3 years.

  • ProfitabilityStrong

    ROCE 24.5% vs peer median 17.9%.

  • Balance sheetStretched

    Practically debt-free, Piotroski 3 of 9.

  • Red flags1 to check

    Quarterly profit down 23.4% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹4,224 Cr, #47 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹764 Cr · profit ₹109 Cr
Market cap
₹4,224 Cr
Small cap
P/E
38.1
Industry 28.7
Price to book
5.79
Peers 4.99
Dividend yield
0.94%
ROE
15.6%
Peers 14.7%
ROCE
24.5%
Peers 17.9%
Debt to equity
0.03
Debt ₹26 Cr
EPS (TTM)
₹67.01
Face value ₹8
OPM (TTM)
20.5%
Net margin 14.3%
Sales growth
+16.5%
Latest quarter vs a year ago
Profit growth
−23.4%
Latest quarter vs a year ago
Price to sales
5.53
EV/EBITDA 24.9

Strengths and risks

Strengths

  • Return on capital employed of 24.5%.
  • Practically debt-free.
  • Quarterly sales up 16.5% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Quarterly profit down 23.4% on a year ago.

Derived automatically from reported figures. Not a recommendation.

About RPG Life Sciences

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and…

Headquarters
Mumbai
Employees
1,366
Sector
Healthcare
ISIN
INE105J01010
Website
rpglifesciences.com

Price range

52 weeks

₹1,733.00₹3,127.80

Today

₹2,520.10₹2,580.00
Avg volume (3M)
27.5K
1-year return
plus 5.4%
From 52-week high
minus 18.4%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
RPGLIFERPG Life Sciences2,553.70minus 1.62%4,22438.15.7924.5%20.3%21.0%11.3%19.4%0.94%plus 5.4%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Dec 25Mar 26Jun 26Sep 26
169180177196212
133140144152171
35.539.832.843.340.4
21.0%22.1%18.6%22.1%19.1%
5.23.412.44.74.3
0.10.30.40.60.8
5.15.45.75.96.8
–−8.41.1––
35.429.140.241.537
25.8%24.0%25.6%25.8%23.8%
26.322.129.930.826.6
15.9013.3818.0818.6017.07

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+11.3%
Profit CAGR 3Y
+19.4%
EPS CAGR 3Y
+19.4%
ROE
15.6%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
509577648702
–+13.4%+12.1%+8.4%
405448486554
104129162148
20.5%22.4%25.0%21.1%
2.50.42.410.1
0.30.50.60.9
15.517.121.421.5
0.75.890.718.3
91.7118233154
26.2%25.6%21.3%25.3%
67.687.7183115
–+29.6%+109.0%minus 37.1%
40.9053.01110.8069.64

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
13.213.213.213.2
294362517592
0––20
112138127168
419513658793
116182165212
1584.8420
–111
115126265274
173119223286
419513658793

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
90.894.477.956.5
−106−79.2−41.885.8
−17.1−20.3−27.1−20.6
−32.1−5.19122
−32.7−69.2−36−65.4
58.125.141.8−8.9
−15.9−19.9−26.5−39.7

Shareholding pattern

Source: NSE filings
73.0%
promoters
  • Promoters72.95%
  • Public27.05%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202672.95%27.05%0.00
30 Jun 202672.95%27.05%0.00
31 Mar 202672.95%27.05%0.00
31 Dec 202572.95%27.05%0.00
30 Sep 202572.95%27.05%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you